Market Newsdesk

HCSC Covers Approximately 17 Million Members Across Five States

Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

SEATTLE–(BUSINESS WIRE)–
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of industry veteran Zelanna Goldberg, M.D., M.A.S. as its Chief Medical Officer. Dr. Goldberg joins Alpine from Iovance Biotherapeutics, where she was Senior Vice President, Clinical Science.

“We are very enthusiastic about the addition of Zelanna to the Alpine team, particularly as we pursue an expanding scope of clinical development activities across oncology and inflammatory disease indications,” said Stanford Peng, M.D., Ph.D., President and Head of Research and Development at Alpine. “Zelanna is an experienced clinical development executive with a commitment to helping patients with life-threatening and debilitating diseases.”

“I am thrilled to join Alpine and lead the clinical strategy and development of the company’s extremely promising pipeline, including ALPN-101, ALPN-202, and ALPN-303,” said Dr. Goldberg. “I look forward to integrating within the research and development team to continue to advance these unique therapies and those that are coming next from Alpine’s directed evolution platform to meaningfully improve the lives of patients with cancer and life-threatening auto-immune diseases.”

Dr. Goldberg brings over 20 years of industry and clinical practice experience, including strategic and/or operational responsibility for multiple therapeutic products such as dacomitinib (Vizimpro), palbociclib (Ibrance), and avelumab (Bavencio). Most recently, Dr. Goldberg was Senior Vice President, Clinical Sciences at Iovance Biotherapeutics, where she oversaw multiple aspects of the clinical development program of lifileucel (LN-145). Prior to Iovance, Dr. Goldberg held roles of increasing responsibility at Sunesis, Oxigene and Pfizer, where she was the global clinical lead for multiple assets. Prior to entering industry, Dr. Goldberg was an Associate Professor in the Department of Radiation Oncology at the University of California, Davis Medical Center.

Dr. Goldberg received her M.D. degree from University of Toronto Faculty of Medicine. Dr. Goldberg completed her residency in Radiation Oncology at Ontario Cancer Institute/Princess Margaret Hospital-University of Toronto, and her post-doctoral training in radiosensitizing drugs at Stanford University.

Disclosure of Inducement Grant under Nasdaq Listing Rules

The compensation committee of Alpine’s board of directors granted Dr. Goldberg an option to purchase 160,000 shares of common stock. The option will vest with respect to 25% of the shares underlying the option on the one-year anniversary of Dr. Goldberg’s employment start date of June 1, 2021, and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36-month period following the one-year anniversary of Dr. Goldberg’s employment start date, subject to her continued service to Alpine through each relevant vesting date. In addition, pursuant to the terms of Alpine’s change of control and severance policy, if there is a change of control and, upon or during the 12 months after the change of control, Dr. Goldberg’s employment is terminated either (i) by Alpine without cause or (ii) by Dr. Goldberg for good reason, the option will become fully vested and exercisable. The option has a ten-year term and an exercise price of $10.29, equal to the per share closing price of Alpine’s common stock as reported by Nasdaq on June 1, 2021.

The stock options were granted outside Alpine’s 2018 Equity Incentive Plan as an inducement material to Dr. Goldberg entering into employment with Alpine in accordance with Nasdaq Listing Rule 5635(c)(4). The terms and conditions of the option are generally consistent with those in Alpine’s 2018 Equity Incentive Plan.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding Alpine’s platform technology, potential therapies, future development plans, clinical and regulatory objectives and the timing thereof, and expectations regarding the potential efficacy and commercial potential of Alpine’s and its collaborator’s product candidates. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our product candidates; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

“Secreted Immunomodulatory Proteins”, “SIP”, “Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005397/en/

Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc.

206-788-4545

[email protected]

Laurence Watts

Managing Director

Gilmartin Group, LLC.

619-916-7620

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Oncology Health Other Health Research Science Pharmaceutical Biotechnology

MEDIA:

Posted on June 2, 2021 8:10 am

Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical

Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical

Technology transfer to Qilu Pharmaceutical on track for completion in 2021

Sesen Bio to receive $2M milestone payment upon completion of technology transfer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Tuesday, June 1, 2021 the Company entered into a global supply agreement for Vicineum™ drug substance and drug product with the Company’s partner in China, Qilu Pharmaceutical.

Under the terms of the global supply agreement, Qilu Pharmaceutical will be part of the manufacturing network for global commercial supply of Vicineum drug substance and drug product. In February 2021, the U.S. Food and Drug Administration (FDA) accepted for filing the Company’s Biologics License Application (BLA) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and granted the application Priority Review, with a target Prescription Drug User Fee Act (PDUFA) date of August 18, 2021. The Company anticipates initiating promotion to physicians and patients in the US upon approval, with commercial product supply broadly available to urology clinics by the fourth quarter of 2021.

In December 2020, Sesen Bio entered into a commercial manufacturing and supply framework agreement with Qilu Pharmaceutical in which both parties aligned on key components of the structure of a global supply partnership. The new global supply agreement with Qilu Pharmaceutical builds on the Company’s existing partnership by setting specific terms such as capacity, forecasts, pricing and product delivery. The completion of the global supply agreement expands the Company’s network of world-class partners committed to providing reliable supply of Vicineum worldwide. Sesen Bio is entitled to a $2 million milestone payment upon completion of technology transfer to Qilu Pharmaceutical, which the Company believes is on track for completion in 2021.

“Given the chronic product shortage issues that exist for patients with NMIBC, we have thoughtfully developed what we believe to be a very reliable and robust supply chain with world-class manufacturing partners,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “Qilu Pharmaceutical has extensive biomanufacturing expertise and experience supplying products for commercial sale around the world, which positions them well to support the anticipated significant global demand for Vicineum.”

Sesen Bio also continues to support Qilu Pharmaceutical in the development and commercialization of Vicineum in China. In March 2021, the Investigational New Drug (IND) application for Vicineum was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) thereby triggering a $3 million milestone payment to Sesen Bio, which the Company received, net of taxes, on May 24, 2021. The approval of the IND enables Qilu Pharmaceutical to conduct the proposed clinical trial to assess the efficacy and safety of Vicineum for patients in China. It is anticipated that the first patient will be dosed in the trial within the next month. Assuming a successful trial, Qilu Pharmaceutical anticipates submission of the product market application for Vicineum in 2022 with potential approval in China expected in 2023.

About Vicineum™

Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by the cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells. Sesen Bio is currently in the follow-up stage of a Phase 3 registration trial in the US for the treatment of BCG-unresponsive NMIBC. In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and granted the application Priority Review with a target PDUFA date of August 18, 2021. Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. For this reason, the activity of Vicineum in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as oportuzumab monatox, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and granted the application Priority Review with a target PDUFA date of August 18, 2021. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of BCG-unresponsive NMIBC. For more information, please visit the Company’s website at www.sesenbio.com.

About Qilu Pharmaceutical

Qilu Pharmaceutical is a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. With a diverse pipeline of novel therapeutics, 10 manufacturing sites and more than 23,000 employees worldwide, Qilu Pharmaceutical is dedicated to transforming scientific innovation by internal R&D across 5 R&D platforms based in the US (Seattle WA, Boston MA, San Francisco CA) and China (Shanghai, Jinan), and external partnership globally into healthcare solutions to address unmet medical needs. To date, Qilu Pharmaceutical has launched 200+ products with 30+ products “First to launch” in China and 3 products “D181 launch” in US.

COVID-19 Pandemic Potential Impact

Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on the Company. The Company has not yet experienced any disruptions to our operations as a result of COVID-19, however, we are not able to quantify or predict with certainty the overall scope of potential impacts to our business, including, but not limited to, our ability to raise capital and, if approved, commercialize Vicineum. Sesen Bio remains committed to the health and safety of patients, caregivers and employees.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: dependence on third parties for the Company’s supply chain for Vicineum, requirements to demonstrate product manufactured by third parties is comparable to that used in the Company’s clinical trials, the timing and receipt by the Company of any milestone payments from Qilu Pharmaceutical, the timing for completion of the manufacturing technology transfer with Qilu Pharmaceutical, the timing for the FDA’s decision on the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC based on the FDA granting the BLA Priority Review and the target PDUFA date of August 18, 2021, the impact of COVID-19 on the Company, including its ability to raise capital, and, if approved, its ability to commercialize Vicineum for the treatment of BCG-unresponsive NMIBC, the timing and results of any clinical trial for Vicineum in China, the timing for submission and potential approval of the product market application for Vicineum for the treatment of BCG-unresponsive NMIBC to the National Medical Products Administration, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005300/en/

Erin Clark, Vice President, Corporate Strategy & Investor Relations

[email protected]

KEYWORDS: Massachusetts China United States North America Asia Pacific

INDUSTRY KEYWORDS: Research General Health Supply Chain Management Pharmaceutical Oncology Other Manufacturing Retail Clinical Trials Science Biotechnology FDA Health Manufacturing

MEDIA:

Logo

Janus International Secures Contracts with Strat Property Management Inc. and SmartStop Self Storage to Implement Nokē® Smart Entry Solutions

Two of the Industry’s Largest Owner Operators Select Nokē® by Janus as Go-Forward Smart Access Control Solution

TEMPLE, Ga.–(BUSINESS WIRE)–
Janus International Group, LLC (“Janus” or the “Company”), a leading global manufacturer and supplier of turn-key building solutions and new access control technologies for the self-storage industry, announced today that two of the largest independent self-storage owner operators in North America have signed agreements to implement its Nokē^® Smart Entry (“Nokē Smart Entry” or “Nokē”) smart access control and security solutions. Strat Property Management, Inc., (“SPMI”), a real estate and management firm primarily focused in the self-storage and multi-family industries, and SmartStop Self Storage REIT, Inc. (“SmartStop”), a self-managed REIT that owns and operates nearly 150 self-storage facilities, will be implementing the Nokē Smart Entry system across multiple properties in their respective portfolios.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005375/en/

“We are thrilled to partner with forward-thinking self-storage owner operators like SPMI and SmartStop as they look to provide a more modern, convenient, and secure experience for their customers,” said Christine DeBord, President of Nokē. “We’re excited these two industry leaders have chosen Nokē Smart Entry as their smart access control and security solution and are pleased to see such rapid growth and adoption of the solution within the industry.”

San Diego, CA. based SPMI has already implemented the Nokē system at multiple locations and have committed to equipping at least 20 percent of their 70+ store portfolio with Nokē^® ONE (“Nokē ONE”) smart locks by the end of 2021. Additionally, SPMI has committed to replacing 5,000 existing unit doors with new Janus doors locks and replace 135 access control keypads with Janus’ smart “Nokēpads” to enable mobile access for customer convenience and enhanced security. Over the next three years, SPMI intends to have Nokē ONE smart locks at every location.

Don Clauson, Owner and CEO of SPMI, commented, “We look forward to refreshing our Texas and California portfolios by installing Janus’s best-in-class doors and innovative smart locking solution, as we believe that investing in our facilities is integral to delivering an excellent customer experience. We chose to partner with the Janus team on these projects because of their track record of providing industry-leading, high-quality doors and hallways as well as innovative smart security solutions. We know that the Janus team is always there to support us as we make value-add improvements to our portfolio. Janus has first class people and products and we’re committed to our ongoing partnership.”

Janus has also signed a contract with SmartStop to add approximately 5,000 Nokē smart locks across five new construction projects expected to complete construction in 2021 and early 2022. SmartStop is the tenth largest self-storage company in the U.S., with approximately $1.7 billion of real estate assets under management, including an owned and managed portfolio of 152 properties in 19 states and Toronto, Canada and comprising approximately 103,000 units and 11.6 million rentable square feet.

Wayne Johnson, President and Chief Investment Officer of SmartStop, said, “SmartStop is committed to delivering cutting-edge technologies and unparalleled service to our customers across North America. As we plan our new construction projects, we are intently focused on building modern facilities that increase efficiency for our operations team and ease of use for our customers. We are pleased to install Nokē smart locks across five of our new developments and look forward to offering our customers a higher level of security and a more convenient storage experience through innovative technology solutions.”

Janus expects to complete its business combination with Juniper Industrial Holdings, Inc. (NYSE: JIH) and become a publicly listed company soon after the special meeting of shareholders scheduled for June 3, 2021. Clearlake, an investment firm, is the largest shareholder in Janus.

For more information about Nokē, please visit: https://www.janusintl.com/products/noke.

ABOUT JANUS INTERNATIONAL

Janus International Group, LLC (www.JanusIntl.com) is the leading global manufacturer and supplier of turn-key self-storage, commercial and industrial building solutions, including: roll-up and swing doors, hallway systems, re-locatable storage units and facility and door automation technologies. The Janus team operates out of several U.S. locations and six locations internationally.

ABOUT STRAT PROPERTY MANAGEMENT

Strat Property Management, Inc. is a real estate development and management firm that focuses on the multifamily housing and self storage classes of real estate. SPMI owns and manages more than 30 apartment buildings and complexes in San Diego, California and more than 65 self storage facilities in five states. For renters, SPMI strives to create an experience that is easy, convenient, and of incredible value. As an organization, SPMI works daily to equip its team of self storage and multifamily housing professionals with everything they need to grow personally and professionally. SPMI is based in San Diego, California. For more information, please visit www.stratprop.com.

ABOUT SMARTSTOP SELF STORAGE REIT, INC. (SmartStop)

SmartStop is a self-managed REIT with a fully integrated operations team of approximately 400 self storage professionals focused on growing the SmartStop® Self Storage brand. SmartStop, through its indirect subsidiary SmartStop REIT Advisors, LLC, also sponsors other self storage programs. SmartStop is the tenth-largest self storage company in the U.S., with approximately $1.7 billion of real estate assets under management, including an owned and managed portfolio of 154 properties in 19 states and Toronto, Canada and comprising approximately 104,000 units and 11.8 million rentable square feet. SmartStop and its affiliates own or manage 17 operating self storage properties in the Ontario, Canada, which total approximately 14,300 units and 1.5 million rentable square feet. Additional information regarding SmartStop is available at www.smartstopselfstorage.com.

ABOUT CLEARLAKE

Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.^® The firm’s core target sectors are industrials, technology, and consumer. Clearlake currently has approximately $38 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

ABOUT JUNIPER INDUSTRIAL HOLDINGS, INC. (NYSE: JIH)

Juniper Industrial Holdings, Inc., a Delaware corporation (“JIH” or “Juniper”), is a Special Purpose Acquisition Corporation targeting companies within the industrials sector. With $348 million in trust, Juniper was formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Juniper’s management team has a proven track record of identifying market-leading technologies across the industrial spectrum, and an affinity for businesses with strong brands and mission-critical offering. The Juniper team has a robust network of relationships within industrial and investment communities built over 60+ years of combined industry experience, and a deep understanding of industrial trends. More information is available at www.juniperindustrial.com.

IMPORTANT INFORMATION AND WHERE TO FIND IT

This communication is being made in connection with the proposed business combination involving Juniper and Janus under a new holding company, Janus Parent, Inc., a Delaware corporation (“Janus Parent”). In connection with the proposed transactions, Janus Parent has filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (as amended, the “Registration Statement”) containing a definitive proxy statement of Juniper and a definitive prospectus of Janus Parent. This announcement does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. Juniper’s shareholders and other interested persons are advised to read the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about Juniper, Janus, Janus Parent and the business combination. Janus Parent has mailed the definitive proxy statement/prospectus and other relevant materials for the proposed business combination to shareholders of Juniper as of May 4, 2021 for voting on the proposed business combination. Shareholders are also able to obtain copies of the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, at the SEC’s website at www.sec.gov. In addition, the documents filed by Juniper and Janus Parent may be obtained free of charge from Juniper at www.juniperindustrial.com/investors. Alternatively, these documents can be obtained free of charge by directing a request to: Juniper Industrial Holdings, Inc., 14 Fairmount Avenue, Chatham, New Jersey 07928.

PARTICIPANTS IN THE SOLICITATION

Juniper, Janus and certain of their directors and executive officers may be deemed participants in the solicitation of proxies from Juniper’s shareholders with respect to the proposed business combination. A list of the names of those directors and executive officers and a description of their interests in Juniper is contained in Juniper’s annual report on Form 10-K for the fiscal year-ended December 31, 2020, which is available free of charge at the SEC’s web site at www.sec.gov. In addition, the documents filed by Juniper may be obtained from Juniper as described above under “Important Information and Where to Find It.”

NO OFFER OR SOLICITATION

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction.

FORWARD LOOKING STATEMENTS

Certain statements in this communication may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this communication are forward-looking statements. When used in this communication, words such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions, as they relate to the management team, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of the respective management of Janus and Juniper, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in Juniper’s filings with the SEC including, but not limited to, the risk factors and other uncertainties set forth under “Risk Factors” in Part I, Item 1A of Juniper’s Form 10-K for the year ended December 31, 2020 and in Juniper’s other filings. There can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and neither Janus nor Juniper is under any obligation, and each of them expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to Janus or Juniper or persons acting on its behalf are qualified in their entirety by this paragraph.

In addition to factors previously disclosed in Juniper’s reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: (i) ability to meet the closing conditions to the merger, including approval by stockholders of Juniper on the expected terms and schedule and the risk that any regulatory approvals required for the merger are not obtained or are obtained subject to conditions that are not anticipated; (ii) the occurrence of any event, change or other circumstance that could cause the termination of the merger agreement or a delay in the closing of the merger; (iii) the effect of the announcement or pendency of the proposed merger on Juniper’s business relationships, operating results, and business generally; (iv) failure to realize the benefits expected from the proposed transaction; (v) risks that the proposed merger disrupts Janus’s current plans and operations and potential difficulties in Janus’s employee retention as a result of the proposed merger; (vi) the effects of pending and future legislation; (vii) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (viii) the amount of the costs, fees, expenses and other charges related to the merger; (ix) risks of the self-storage industry; (x) the highly competitive nature of the self-storage industry and Janus’s ability to compete therein; (xi) litigation, complaints, and/or adverse publicity; (xii) the ability to meet NYSE’s listing standards following the consummation of the proposed transaction and (xiii) cyber incidents or directed attacks that could result in information theft, data corruption, operational disruption and/or financial loss.

This communication is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Juniper and is not intended to form the basis of an investment decision in Juniper. All subsequent written and oral forward-looking statements concerning Janus and Juniper, the proposed transaction or other matters and attributable to Janus and Juniper or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Juniper and Janus undertake no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005375/en/

Investor Contacts, Janus

Rodny Nacier/ Brad Cray

Phone: 770-562-6399

Email: [email protected]

Media Contacts, Janus

Phil Denning / Nora Flaherty

[email protected]

Media Contacts, Clearlake

Jennifer Hurson

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Architecture Commercial Building & Real Estate Construction & Property Textiles Building Systems REIT Manufacturing Residential Building & Real Estate

MEDIA:

Logo

Logo

Logo

Philip Morris International Inc. (PMI) Hosts Webcast on Sustainability and Impact in the Company’s Next Growth Phase

NEW YORK–(BUSINESS WIRE)–
Regulatory News:

Philip Morris International Inc.’s (NYSE:PM) Chief Executive Officer, Jacek Olczak, Chief Financial Officer, Emmanuel Babeau, and Chief Sustainability Officer, Jennifer Motles, will host a webcast presentation today on sustainability and impact in the company’s next growth phase, the subject of its recent Investor Day. Joining them for the Q&A session will be Dr. Moira Gilchrist, Vice President, Strategic & Scientific Communications.

“We are very excited to host our first webcast on ESG performance and sustainability strategy,” said Jacek Olczak, Chief Executive Officer. “Sustainability is core to the transformation of our company, which is based on a deep sense of purpose to create value for our shareholders and other stakeholders.”

“Our priority is to address the health impact of our products, putting them at the core of our sustainability efforts, 2025 aspirations, and commitment to accelerate the end of smoking,” Jacek continued. “But we are also aiming for excellence across traditional ESG areas. In this regard, we are proud to announce that we now expect to reach our 2030 Scope 1 & 2 carbon neutrality target five years ahead of schedule.”

Webcast Details

The presentation and Q&A session will be conducted in a virtual format, beginning at approximately 9:00 a.m. Eastern Time. A live video webcast of the entire PMI session will be available, in a listen-only mode, at www.pmi.com/2021esg. Presentation slides will be available on the same site.

An archived copy of the webcast will be available at www.pmi.com/2021esg until Thursday, July 1, 2021. The archived webcast can also be accessed on iOS or Android devices by downloading PMI’s free Investor Relations Mobile Application at www.pmi.com/irapp.

2020 Integrated Report

The webcast follows the recent release of PMI’s 2020 Integrated Report, along with a new section for PMI’s website covering sustainability. The report provides a comprehensive overview of the company’s approach to ESG topics and its progress toward delivering a smoke-free future. The report also highlights PMI’s most material sustainability topics—including the health impacts of its products, an aspect often not captured by external ESG assessments—and describes how the company is researching and developing scientifically substantiated better alternatives than continued smoking for those adults who do not quit.

To complement the Integrated Report, PMI has also prepared an ESG Highlights document, which summarizes the report in a more data-driven format and provides direct access to indexes mapping its disclosures to internationally recognized frameworks (including GRI, SASB, Sustainable Development Goals (SDGs) and the IBC/WEF’s Measuring Stakeholder Capitalism).

Forward-Looking and Cautionary Statements

This press release contains projections of future results and other forward-looking statements. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI’s business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; changes in adult smoker behavior; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of our information systems and effectiveness of our data privacy policies. PMI’s future profitability may also be adversely affected if we are unsuccessful in our attempts to produce and commercialize reduced-risk products (“RRPs”) or if regulation or taxation do not differentiate between such products and cigarettes; if we are unable to successfully introduce new products, promote brand equity, enter new markets or improve our margins through increased prices and productivity gains; if we are unable to expand our brand portfolio internally or through acquisitions and the development of strategic business relationships; or if we are unable to attract and retain the best global talent. Future results are also subject to the lower predictability of our reduced-risk product category’s performance.

The COVID-19 pandemic has created significant societal and economic disruption, and resulted in closures of stores, factories and offices, and restrictions on manufacturing, distribution and travel, all of which will adversely impact our business, results of operations, cash flows and financial position during the continuation of the pandemic. Our business continuity plans and other safeguards may not be effective to mitigate the impact of the pandemic. Currently, significant risks include our diminished ability to convert adult smokers to our RRPs, significant volume declines in our duty-free business and certain other key markets, disruptions or delays in our manufacturing and supply chain, increased currency volatility, and delays in certain cost saving, transformation and restructuring initiatives. Our business could also be adversely impacted if key personnel or a significant number of employees or business partners become unavailable due to the COVID-19 outbreak. The significant adverse impact of COVID-19 on the economic or political conditions in markets in which we operate could result in changes to the preferences of our adult consumers and lower demand for our products, particularly for our mid-price or premium-price brands. Continuation of the pandemic could disrupt our access to the credit markets or increase our borrowing costs. Governments may temporarily be unable to focus on the development of science-based regulatory frameworks for the development and commercialization of RRPs or on the enforcement or implementation of regulations that are significant to our business. In addition, messaging about the potential negative impacts of the use of our products on COVID-19 risks may lead to increasingly restrictive regulatory measures on the sale and use of our products, negatively impact demand for our products, the willingness of adult consumers to switch to our RRPs and our efforts to advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs.

The impact of these risks also depends on factors beyond our knowledge or control, including the duration and severity of the pandemic, its recurrence in our key markets, actions taken to contain its spread and to mitigate its public health effects, and the ultimate economic consequences thereof.

PMI is further subject to other risks detailed from time to time in its publicly filed documents, including the Form 10-Q for the quarter ended March 31, 2021. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI’s smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005587/en/

Philip Morris International

Investor Relations:

New York: +1 (917) 663 2233

Lausanne: +41 (0)58 242 4666

[email protected]

Media:

Lausanne: +41 (0)58 242 4500

[email protected]

KEYWORDS: New York United States North America Canada

INDUSTRY KEYWORDS: Environment Other Philanthropy Retail Tobacco Philanthropy

MEDIA:

Logo

Bright Horizons Joins White House to Offer Free Child Care for Vaccines

NEWTON, Mass.–(BUSINESS WIRE)–
Bright Horizons (NYSE: BFAM) has teamed up with the White House to offer free child care to help Americans get their COVID-19 vaccine. The initiative will help achieve the administration’s critical goal of getting 70% of American adults vaccinated by July 4. With summer break approaching, working parents have expressed concern over how and when they will be able to make it to a vaccination appointment.

Bright Horizons partners with employers who collectively represent 10 million Americans to provide back-up care and together they will support parent access to vaccinations and give their employees the support they need to protect their health and health of their families. Starting immediately, employees at Mars, Levi Strauss, Santander and USAA, as well as other participating organizations, can secure back-up child care at a Bright Horizons early education and child care centers while they receive their first dose, second dose, or if they need time to recover from any side effects of the vaccination. Employees can access the free child care through July 4.

“We are proud to stand with the White House to help get our nation vaccinated against COVID-19 and support parents in their effort to keep their family and children safe. While young children are still unable to be vaccinated themselves, the best thing we can do to keep them healthy is to get those who live with, care for and teach children, inoculated against COVID-19,” said Stephen Kramer, Bright Horizons Chief Executive Officer. “We are proud of our client partners who are stepping up to support their employees in protecting their health and getting vaccinated.”

In addition to providing free child care for parents to get vaccinated, Bright Horizons has been providing a $100 incentive for its own teachers and employees to get vaccinated as part of a comprehensive education and awareness campaign to encourage COVID-19 vaccinations and maintaining healthy workplaces.

The company has also been a leader in research to understand the lasting impacts of COVID-19 on working parents and their children’s development. The latest research can be found here: https://www.brighthorizons.com/newsroom/2021-modern-family-index.

A sample of participating employers includes:
Altria		Mars, Incorporated
Ally		MUFG
Cadence		RSM
COTA (Central Ohio Transit Authority)		Santander
Cummins Power Generation Inc.		T. Rowe Price
Edwards		TIAA
Dimensional Fund Advisors		USAA
Levi Strauss		ViaSat

Parents with access to Bright Horizons Back-up Care benefits can book their free child care here: https://www.brighthorizons.com/careforournation.

About Bright Horizons

Bright Horizons® is a leading global provider of high-quality child care and early education, back-up care, and workplace education services. For more than 30 years, we have partnered with employers to support workforces by providing services that help working families and employees thrive personally and professionally. We operate approximately 1,000 child care centers in the United States, the United Kingdom, the Netherlands, and India, and serve more than 1,300 of the world’s leading organizations. Bright Horizons’ child care centers, back-up child and elder care, and workforce education programs, including tuition program management, education advising, and student loan repayment, help employees succeed at each life and career stage. For more information, go to www.brighthorizons.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005366/en/

Michelle DeLuties

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Medical Supplies General Health Health Other Education Children Infectious Diseases Consumer Education

MEDIA:

Logo

Agilent Announces New SureSelect Human All Exon V8

Design provides comprehensive content and flexible exome options

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The new design is available in three options – routine exome sequencing (Exome v8), clinical researchsequencing (v8 Clinical Plus), and translational research (v8 UTR Plus) – allowing for content flexibility to meet our customer’s needs.

Powered by machine learning-based probe design and an improved probe-printing process, the SureSelect Human All Exon V8 spans a 35.1 Mb target region of the human genome, with an efficient end-to-end design size of only 41.6 Mb. The panel delivers excellent enrichment performance for more uniform coverage, as well as efficient and cost-effective exome sequencing.

Kevin Meldrum, vice president and general manager for Agilent’s Genomics Division, discussed the impact of the release. “The SureSelect exome has been widely adopted in both clinical and translational research, and it has played an important role in shaping the rise of exome sequencing as a routine genomics technique,” he said. “The SureSelect Human All Exon V8 provides best-in-class enrichment performance and sequencing efficiency, and it shows our commitment to exceed customer expectations and continue our legacy as the benchmark exome to the genomics community.”

This new exome design is already delivering promising results in genetics by supporting virtual analysis of targeted genes important in germline investigations through seamless integration with Alissa Interpret for variant interpretation and reporting. In cancer, exome sequencing is commonly used to identify mutations that contribute to tumor progression, and the sequencing efficiency and coverage achieved with this new design will enable customers to get more out of each exome capture than ever before to identify critical genomic targets. In addition, large-scale manufacturing ensures the panel will provide consistent results for many years, another critical need in clinical research laboratories.

These new Exome designs can be automated on the Bravo automated liquid handling platform for high throughput applications and the Magnis NGS Prep System for complete, walkaway automation. The complete, pushbutton automation provided by the Magnis system will allow laboratories to efficiently deploy exome sequencing while reducing labor and operational expenses.

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005348/en/

Naomi Goumillout

Agilent Technologies

+1.781.266.2819

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Health Technology Genetics Software Biotechnology

MEDIA:

Logo